
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech is an immuno-pharma company with a strong pipeline of potential treatments for a variety of illnesses, including cancers, viral diseases, and immune-deficiency disorders. The company has a positive outlook due to its ongoing clinical trials, potential for positive clinical data, and a strong balance sheet. However, as with any biotech company, there are risks involved, such as the potential for failure of product candidates and difficulties with gaining regulatory approvals. Overall, AIM ImmunoTech has solid potential and its progress in clinical trials should be closely monitored.
Bears say
AIM ImmunoTech is currently a high-risk investment due to its balance sheet and liquidity risks, failure of product candidates in clinical trials, and competition, which leads to a negative outlook. However, the company has shown positive data in its Phase 1 and Phase 2a studies for Ampligen, providing potential for future growth. The current valuation is attractive, but the risks must be carefully considered in any investment decision.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares